Showing 471-480 of 5000 results for "".
Novel PsO Drug Could Be 'Closest Perception of a Cure,' Dr. Strober Says at Maui Derm
https://reachmd.com/programs/practical-dermatology/novel-pso-drug-could-be-closest-perception-of-a-cure-dr-strober-says-at-maui-derm/32922/A novel monoclonal antibody targeting IL-23 for the treatment of psoriasis offers an extended half-life that will be a key differentiator for patients, according to Bruce Strober, MD, PhD.Dr. Eichenfield Urges Caution for Steroid-Phobia at Maui Derm
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/dr-eichenfield-urges-caution-for-steroid-phobia-at-maui-derm/32919/In addition to the various clinical skin conditions that pediatric patients present with, dermatologists now must understand how to deal with steroid-phobia, according to Lawrence Eichenfield, MD.Growth Potential of the Aesthetic Market
https://practicaldermatology.com/series/c-suite-chats/growth-potential-of-the-aesthetic-market/29746/Merz Aesthetics President, North America, Patrick Urban discusses why he expects demand for aesthetic treatments to continue increasing and how to capitalize on it.What people want and why it matters
https://practicaldermatology.com/topics/general-topics/what-people-want-and-why-it-matters/19526/Our patients differ in both their skin biology and their use of skin care products on a daily basis. Discover how understanding the behaviors and practices of men and women can allow better and more effective product recommendations.Drug-Induced Dermatomyositis
https://practicaldermatology.com/topics/atopic-dermatitis/drug-induced-dermatomyositis/23357/It’s common practice to screen for underlying malignancy in dermatomyositis, but it is also important to look for drug-induced disease.Are We Overlooking Skin Cancer in Ethnic Minorities?
https://practicaldermatology.com/issues/supplements/are-we-overlooking-skin-cancer-in-ethnic-minorities/21718/Skin cancers in Hispanic and African American patients may be detected at more advanced stages, leading to poorer prognoses and long-term outcomes compared to non-Hispanic whites.Upadacitinib and Cardiovascular Events in AD
https://practicaldermatology.com/issues/october-2025/upadacitinib-and-cardiovascular-events-in-ad/39755/A recent review examined whether upadacitinib, a selective Janus kinase 1 (JAK1) inhibitor approved for atopic dermatitis (AD) and other chronic inflammatory diseases, may—despite a boxed warning to the contrary—confer cardioprotective and thromboprotective effects.Curing Z73.89 (a.k.a. Physician Burnout)
https://practicaldermatology.com/topics/practice-management/curing-z7389-aka-physician-burnout/20755/Technology might be the key to finding balance.Pipeline and Potential Roles for GLP-1RAs in Dermatology
https://practicaldermatology.com/issues/novemberdecember-2025/pipeline-and-potential-roles-for-glp-1ras-in-dermatology/48898/Having reviewed the mechanism of action and current roles in medicine for glucagon-like peptide 1 receptor agonists (GLP-1RAs), we now can discuss therapies in this class currently under investigation for management of dermatologic disease.Clinical Focus: Psoriasis: New Data on Comorbidities Associated with Psoriasis
https://practicaldermatology.com/topics/psoriasis/new-data-on-comorbidities-associated-with-psoriasis/21979/With data mounting, it is essential that dermatologists monitor all patients who may be at risk for comorbidities and provide referrals when indicated.